These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 26848870)

  • 1. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice.
    Zhang M; Jiang H; Zhang R; Jiang H; Xu H; Pan W; Gao X; Sun Z
    J Cell Biochem; 2019 Jun; 120(6):10239-10247. PubMed ID: 30609118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody.
    Pang X; Liu M; Wang R; Liao X; Yan P; Zhang C
    J Labelled Comp Radiopharm; 2018 Sep; 61(11):826-836. PubMed ID: 29923634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-Based
    De Silva RA; Kumar D; Lisok A; Chatterjee S; Wharram B; Venkateswara Rao K; Mease R; Dannals RF; Pomper MG; Nimmagadda S
    Mol Pharm; 2018 Sep; 15(9):3946-3952. PubMed ID: 30037229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.
    Heskamp S; Wierstra PJ; Molkenboer-Kuenen JDM; Sandker GW; Thordardottir S; Cany J; Olive D; Bussink J; Boerman OC; Dolstra H; Aarntzen EHJG; Hobo WA
    Cancer Immunol Res; 2019 Jan; 7(1):150-161. PubMed ID: 30459153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
    Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
    Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
    Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
    MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
    Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
    Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
    Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE
    Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifunctional molecular probe targeting tumor PD-L1 enhances anti-tumor efficacy by promoting ferroptosis in lung cancer mouse model.
    Shao C; Yan X; Pang S; Nian D; Ren L; Li H; Sun J
    Int Immunopharmacol; 2024 Mar; 130():111781. PubMed ID: 38442580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
    Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
    Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Phase I Study of a
    Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
    J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive PD-L1 quantification using [
    Mishra A; Gupta K; Kumar D; Lofland G; Sharma AK; Solnes LB; Rowe SP; Forde PM; Pomper MG; Gabrielson EW; Nimmagadda S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.
    Heskamp S; Hobo W; Molkenboer-Kuenen JD; Olive D; Oyen WJ; Dolstra H; Boerman OC
    Cancer Res; 2015 Jul; 75(14):2928-36. PubMed ID: 25977331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.